Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.33 |
| ▸ | USP2 | O75604 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25044369 | 0.90 | HSD17B10 (0.39) | HSD17B10CYP2D6USP2TSHRCYP3A4 | |
| SCHEMBL17624329 | 0.89 | CYP2D6 (0.34) | HSD17B10CYP2D6USP2TSHRCYP3A4 | |
| SCHEMBL19504447 | 0.84 | KDM1A (0.31) | HSD17B10 | |
| SCHEMBL24940878 | 0.82 | CYP2D6 (0.37) | HSD17B10CYP2D6USP2TSHRCYP3A4 | |
| SCHEMBL17624449 | 0.81 | CYP3A4 (0.39) | CYP2D6USP2TSHRCYP3A4CYP2C9 | |
| SCHEMBL25001373 | 0.80 | CYP2D6 (0.41) | CYP2D6TSHRCYP3A4CYP2C9CYP1A2 | |
| SCHEMBL23443978 | 0.77 | HSD17B10 (0.33) | HSD17B10CYP2D6 | |
| SCHEMBL8257209 | 0.75 | TSHR (0.44) | CYP2D6USP2TSHRCYP3A4CYP1A2 | |
| SCHEMBL23277978 | 0.74 | HSD17B10 (0.36) | HSD17B10CYP2D6USP2TSHRCYP3A4 | |
| SCHEMBL24802218 | 0.74 | TSHR (0.35) | HSD17B10CYP2D6USP2TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230052017-A1 | New compounds for treatment of diseases related to DUX4 expression | SMN1; SMN2, UTRN, DDX21 | HSD17B10 1516/4885CYP2D6 4451/4885USP2 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.